Business Wire

TYAN Highlights New AI, Cloud and Storage Server Platforms Powered by AMD EPYC™ 7003 Series Processors at the TYAN 2021 Online Exhibition

Share

TYAN®, an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, brings a variety of AI, cloud and storage server platforms incorporating the latest AMD EPYC™ 7003 Series processors in TYAN’s 2021 Server Solutions Online Exhibition beginning June 2nd.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005045/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Attendees will experience demonstrations on the latest AMD products and technologies in HPC, cloud, storage, and 5G halls at the 3D virtual environment (Graphic: Business Wire)

“As the continued growth of using clouds for running HPC workloads, modern data center operators need to raise the bar for improved business outcomes,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's Server Infrastructure Business Unit. “With leadership performance and modern security features, TYAN’s 3rd Generation AMD EPYC processor-based platforms empower our customers to drive performance at a competitive price.”

Transport HX products deliver leadership compute in supercomputing and deep learning

Attendees will experience demonstrations on the latest AMD products and technologies in HPC, cloud, storage, and 5G halls at the 3D virtual environment. Leveraging 3rd Generation AMD EPYC processors, the Transport HX TN83-B8251 is a 2U dual-socket server with 16 DDR4-3200 DIMM slots, two half-height, half-length PCIe 4.0 x16 expansion slots for high-speed networking cards, and eight 3.5-inch SATA/NVMe U.2 hot-swap, tool-less drive bays. The platform supports up to four double-width GPU cards that can be easily scaled out to improve HPC and deep learning performance.

The Transport HX TS75A-B8252 is a 2U dual-socket server platform optimized for virtualization applications with support for 32 DDR4-3200/2933 DIMM slots and up to nine PCIe 4.0 x8 slots. The TS75A-B8252 accommodates 26 2.5-inch SATA hot-swap, tool-less drive bays with up to eight NVMe U.2 support by configuration. The Transport HX FT65T-B8030 is a 4U convertible tower server platform designed for cost-effective HPC applications. The system supports a single AMD EPYC 7003 Series processor, eight DDR4-3200 DIMM slots, eight 3.5-inch SATA, and two NVMe U.2 hot-swap, tool-less drive bays. The FT65T-B8030 supports four double-width PCIe 4.0 x16 slots for GPUs to accelerate HPC applications.

Transport CX lineup is designed for cloud and data analytics requiring large memory capacity

The Transport CX GC79-B8252 and Transport CX GC79A-B8252 are 1U dual-socket server platforms that are ideal for high-density data center deployment for a variety of memory-based computing applications. Both systems feature 32 DDR4-3200/2933 DIMM slots, two standard PCIe 4.0 x16 expansion slots, and an OCP 3.0 LAN mezzanine slot. The GC79-B8252 platform provides four 3.5-inch SATA and four 2.5-inch NVMe U.2 hot-swap, tool-less drive bays, while the GC79A-B8252 platform offers twelve 2.5-inch drive bays with up to twelve NVMe U.2 support.

The Transport CX GC68-B8036-LE and Transport CX GC68A-B8036 are cost-optimized single-socket cache server platforms featuring 16 DDR4-3200/2933 DIMMs, a pair of PCIe 4.0 x16 expansion slots and an OCP 2.0 LAN mezzanine slot in a 1U chassis. The GC68-B8036-LE accommodates four 3.5-inch SATA hot-swap, tool-less drive bays for large storage capacity and four 2.5-inch hot-swap, tool-less NVMe U.2 bays for application cache usage; the GC68A-B8036 offers twelve 2.5-inch hot-swap, tool-less drive bays with support for up to twelve NVMe U.2 devices for applications for high storage performance requirements.

The Transport CX TN73-B8037-X4S is a 2U multi-node server platform with four front-serviced compute nodes. Each node supports one AMD EPYC 7003 Series processor, four 2.5-inch hot-swap, tool-less NVMe/SATA drive bays, eight DDR4-3200 DIMM slots, three internal cooling fans, two standard PCIe 4.0 x16 expansion slots, two internal NVMe M.2 slots and one OCP 2.0 LAN mezzanine slot. The platform is suited for high-density data center deployments and targets scale-out applications with large numbers of nodes.

Transport SX lineup to deliver massive I/O and memory bandwidth for storage applications

The Transport SX TS65-B8253 is a 2U dual-socket hybrid software storage server for various datacenter and enterprise deployments supporting 16 DDR4-3200 DIMM slots and seven standard PCIe 4.0 slots. The platform offers twelve front 3.5-inch hot-swap, tool-less SATA drive bays with support for up to four U.2 NVMe SSDs, and two rear 2.5-inch hot-swap, tool-less SATA drive bays for boot drive deployment.

TYAN’s Transport SX TS65-S8036 and Transport SX TS65A-S8036 are 2U single-socket storage servers with support for 16 DDR4-3200/2933 DIMM slots, five PCIe 4.0 and one OCP 2.0 LAN mezzanine slots. The TS65-S8036 accommodates twelve front 3.5-inch and two rear 2.5-inch hot-swap, tool-less SATA drive bays for cloud storage applications, up to four NVMe U.2 devices are supported on the front twelve drive bays; the TS65A-S8036 offers 26 front and two rear 2.5-inch hot-swap, tool-less drive bays for high-performance data streaming applications, the 26 front drive bays can support up to 24 NVMe U.2 devices by configuration.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MiTAC Computing Technology Corporation/ Server Infrastructure Business Unit
Fenny Chen
fenny.chen@tyan.com.tw

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion Healthcare presents the first real-world data for Truxima ® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress12.6.2021 17:45:00 CEST | Press release

Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2021 Virtual Congress.1 CT-P10 was granted European Medicines Agency approval in 2017 for the treatment of rheumatoid arthritis (RA) and specific blood cancers, including non-Hodgkin’s lymphoma (NHL).2 DLBCL is the most common subtype of NHL, representing an estimated 30-40% of adult cases.3,4,5,6 This non-interventional post-authorisation safety study (PASS) involved the collection of patient-level data from hospital medical records for patients with DLBCL who received CT-P10 treatment in five European countries (United Kingdom, Spain, France, Germany and Italy). CT-P10 treatment pattern data were collected retrospectively during the 30-month observation period and patients were selected based on the treatment t

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® ▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible12.6.2021 09:01:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® ▼(daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901). The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI),

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia12.6.2021 09:00:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukaemia (CLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.1 With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing an

Alluzience ® , the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe11.6.2021 11:53:00 CEST | Press release

Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1 "The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues. As

Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World11.6.2021 10:15:00 CEST | Press release

The Secure Communities Forum, a global collaboration of security professionals, has convened a leading panel of experts to discuss how behavioural science can impact positive social cohesion, build on the concept of positive citizenship, and encourage positive individual behaviours. The virtual event was attended by 134 people from 18 countries. The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic. Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing. Lindsay Juarez, Director at Irrational Labs, USA, opened the session, offering the view that we assume humans are rational, which is not the case. She said: “Behavioural science is about setting people up for success and breaking through the noise. Information isn't enough to change behaviour, the decision-making context matters. “People don’t always act in their own long-term best interests,

Luxembourg’s Supercomputer MeluXina is Operational11.6.2021 09:18:00 CEST | Press release

Luxembourg’s high performance computer MeluXina was officially launched on June 7 putting the country on the global map of computer super powers. MeluXina is capable of executing more than 10 Petaflops, the equivalent of 10 million billion calculations per second, which will rank it among the world’s top 50 supercomputers. The petascale computer is powered by green energy and is part-funded under the European High Performance Computing Joint Undertaking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005115/en/ Minister of State Xavier Bettel; His Royal Highness Henri, Grand Duke of Luxembourg; Minister of the Economy Franz Fayot; EuroHPC Joint Undertaking Executive Director Anders Jensen (Photo: Business Wire) In a series of 8 high-performance computers in the EU, MeluXina joins Vega, another petascale supercomputer located in Slovenia, as the first EuroHPC machines to go live. Its innovative modular architecture allo

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting11.6.2021 09:05:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics (Nasdaq:CRSP) today announced new data on 22 patients,with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and sustained response to treatment. CTX001 is being investigated in two ongoing Phase 1/2 clinical trials as a potential one-time therapy for patients suffering from transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). In total, more than 40 patients have been dosed across both studies to date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005069/en/ All 15 patients with TDT, including six who have the beta zero/beta zero or other severe genotypes, were transfusion-free at last follow-up, and all seven patients with severe SCD were free of vaso-occlusive crises (VOCs) from CTX001 infu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom